In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Obesity, Overweight. SEO and diligence focus: Liraglutide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Obesity
Modality: small molecule
Target: Liraglutide
Sponsor: Novo Nordisk A/S
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Liraglutide
View original source fields
Condition raw: Obesity, Overweight
Condition normalized: Obesity, Overweight
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Liraglutide
Target normalized: Liraglutide